Munich, Germany

Veit Peter Grunert

USPTO Granted Patents = 5 

Average Co-Inventor Count = 4.3

ph-index = 2

Forward Citations = 10(Granted Patents)


Company Filing History:


Years Active: 2010-2015

Loading Chart...
5 patents (USPTO):

Title: Veit Peter Grunert: Innovator in Monoclonal Antibody Assessment

Introduction: Veit Peter Grunert is a distinguished inventor based in Munich, Germany, known for his significant contributions to the field of diagnostics and therapeutics. With a total of 5 patents to his name, Grunert's work largely focuses on the measurement and analysis of monoclonal antibodies, a crucial area in contemporary medical research and treatment.

Latest Patents: Among Grunert's latest innovations is the patent for an assay designed for the measurement of antibodies binding to a therapeutic monoclonal antibody. This method and system facilitate the determination of an anti-therapeutic monoclonal antibody antibody (anti-TmAB AB) in vitro from patient samples who are being treated with therapeutic monoclonal antibodies (TmAB). Furthermore, he has developed methods and systems for identifying antigen-specific antibodies of a specific immunoglobulin class and determining patients at risk of adverse drug reactions during TmAB treatments. Additionally, he holds a patent for a method to assess the severity of rheumatoid arthritis by measuring anti-cyclic citrullinated peptides (anti-CCP) and serum amyloid A. This method combines these concentrations to derive a value that can be compared against a cut-off value established from a reference population to evaluate the severity of the condition.

Career Highlights: Veit Peter Grunert's career has flourished at Roche Diagnostics Operations, Inc., where his innovative approach to problem-solving and talent in research have been instrumental. His endeavors in patenting new methodologies demonstrate his commitment to advancing the field of medical diagnostics, helping clinicians make better-informed decisions regarding patient care.

Collaborations: Throughout his career, Grunert has collaborated with esteemed coworkers Johann Karl and Norbert Wild. Working alongside these professionals, he has been able to expand his research capacities and efficiently bring groundbreaking innovations to fruition.

Conclusion: Veit Peter Grunert stands out as a leading inventor in the medical diagnostics field. His valuable patents and innovative methods not only enhance our understanding of therapeutic monoclonal antibodies but also aim to improve patient outcomes significantly. As the industry advances, his contributions will undoubtedly pave the way for future innovations in medical treatment and patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…